Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

<p>Supplementary video 2</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Min Wei (16918572) (author)
Diğer Yazarlar:	Xinping Huang (16918575) (author), Liming Liao (16918578) (author), Yonglu Tian (16918581) (author), Xiaofeng Zheng (16918584) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biochemistry Protein/protein interactions Biomarkers Protein biomarkers Carcinogenesis DNA damage and repair DNA Damage and Repair Drug Resistance Regulation of gene expression in drug resistance Gastrointestinal Cancers Colorectal cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
Yazar:: Min Wei (16918572)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Yazar:: Kavya Ramkumar (16474203)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Yazar:: Marta J. Llorca-Cardenosa (14961612)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Yazar:: Marta J. Llorca-Cardenosa (14961612)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Yazar:: Marta J. Llorca-Cardenosa (14961612)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Yazar:: Marta J. Llorca-Cardenosa (14961612)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Yazar:: Marta J. Llorca-Cardenosa (14961612)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Yazar:: Sanna Pikkusaari (15055802)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Yazar:: Sanna Pikkusaari (15055802)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
Yazar:: Sami Belhadj (15052341)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ikvc1c20j1ef8dckqibj59q216